Dr. Reddy’s unit gets EIR from USFDA

April 09, 2020 10:26 pm | Updated 11:15 pm IST - HYDERABAD

Dr. Reddy’s Laboratories’ active pharmaceutical ingredient (API) manufacturing plant-5 in Miryalaguda of Nalgonda District in Telangana has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA).

“We have received an EIR from USFDA for the facility, indicating closure of the audit and the inspection classification of this facility is determined as voluntary action indicated (VAI), the pharma major said in a filing with the stock exchanges on Thursday.

The USFDA had completed audit of the API manufacturing plant last month and issued a Form 483 with three observations. “We will address them comprehensively within the stipulated timeline,” the company had said in a communication on March 5.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.